Analyst John Young CFA from Canaccord Genuity maintained a Buy rating on AngioDynamics (ANGO – Research Report) and keeping the price target at $15.00.
John Young CFA has given his Buy rating due to a combination of factors that highlight AngioDynamics’ strong performance and growth potential. The company delivered impressive results in the third quarter of fiscal year 2025, surpassing expectations with solid execution in its Med-Tech segment. This has led to an increase in the full-year guidance, reflecting confidence in the company’s continued momentum and the growing legitimacy of its Med-Tech business.
Additionally, AngioDynamics’ management has raised its revenue and profitability guidance for FY25, driven by the high-growth potential of its Med-Tech offerings such as Auryon, Mechanical Thrombectomy, and NanoKnife. These technologies are expected to contribute significantly to the company’s growth, with Auryon offering a promising multimodal laser platform, Mechanical Thrombectomy showing consistent growth in an underpenetrated market, and NanoKnife benefiting from upcoming reimbursement changes. The company’s trajectory toward sustained profitability further supports the Buy rating, as potential stock dilution concerns are likely diminishing.
Young CFA covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Staar Surgical, and AngioDynamics. According to TipRanks, Young CFA has an average return of 18.0% and a 76.92% success rate on recommended stocks.